Advice

Following a full submission

Fondaparinux (Arixtra) is not recommended for use within NHS Scotland for the prevention of venous thromboembolic events (VTE) in patients undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as those undergoing abdominal cancer surgery.

Fondaparinux showed non-inferiority to one other low molecular weight heparin in preventing VTE in patients undergoing abdominal surgery. The economic case has not been demonstrated.

The licence holder has indicated their decision to resubmit.

Download detailed advice46KB (PDF)

Download

Medicine details

Medicine name:
fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra)
SMC ID:
287/06
Indication:
Prevention of venous thromboembolic events
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Cardiovascular system
Submission type
Full
Status
Not recommended
Date advice published
07 August 2006